Committee Also Slams Schedule I And Suggests Cannabis Can Reduce Opioid Addiction.
A powerful Senate panel is urging federal agencies to make a number of surprising marijuana moves, including launching an effort to test products sold at dispensaries in states where cannabis has been legalized.
Concerned about a lack of data on the potency and purity of cannabis available to consumers, the U.S. Senate Appropriations Committee is directing federal agencies to formulate a “National Testing Program for Schedule I Marijuana-Derived Products.”
The senators, in a report issued on Thursday, are instructing scientists at the National Institute on Drug Abuse (NIDA) to work with the Drug Enforcement Administration (DEA) to study marijuana samples in an effort to “provide robust reliable data that can inform policy.”
Until 2014, NIDA funded a program for testing samples of illicit marijuana seized by law enforcement, but has never before officially analyzed cannabis products that are legally available to consumers under a growing number of state laws.
“The Committee believes that such research [on law-enforcement-seized cannabis], along with analysis of marijuana and marijuana-derived products sold commercially in dispensaries or online, is essential for informing substance abuse prevention efforts, public health policy, and law enforcement tactics across the Federal Government.”
It is unknown how such a program would be carried out, for example whether it would involve sending teams of NIDA researchers to dispensaries to purchase marijuana for research, or if it would instead or in addition rely on DEA enforcement actions against the facilities and subsequent testing of seized products.
Separately in the report attached to legislation funding federal health programs, the Appropriations Committee also expressed alarm about “barriers to research” that are created by cannabis’s current status under federal law, and is directing NIDA to compile a report about the matter.
“The Committee is concerned that restrictions associated with Schedule 1 of the Controlled Substance Act effectively limit the amount and type of research that can be conducted on certain schedule 1 drugs, especially marijuana or its component chemicals and certain synthetic drugs,” the report says. “At a time when we need as much information as possible about these drugs, we need to review lowering regulatory and other barriers to conducting this research. The Committee directs NIDA to provide an update…on the barriers to research that result from the classification of drugs and compounds as Schedule 1 substances.”
Schedule I — the most restrictive category — is supposed to be reserved for drugs with no medical value and a high potential for abuse. Researchers have long complained that the classification creates additional hurdles that don’t exist for studies on other substances.
The Senate request is very similar to language that the House Appropriations Committee included in its report on federal health and research spending legislation in July.
In a third marijuana-related move, the senators cited the growing body of research suggesting that cannabis could be a partial solution to opioid overdose and addiction problems.
“Over the past two decades, the dramatic increase in abuse of prescription opioids, non-synthetic opioids, and illicit synthetic opioids has grown to epidemic proportions,” the committee report says. “Scientific rationale and laboratory studies suggest a decrease in addictive potential when botanical derivatives, including cannabidiol extracts, are used with an opioid in treating patients. The Committee supports study of this integrative approach to treatment and urges [federal agencies] to support and facilitate trials aimed at reducing addiction under appropriate [Investigational New Drug] applications.” [Bolded emphasis added.]
The acknowledgment of cannabis components’ potential to reduce opioid problems comes as a Trump administration commission on the issue is completely ignoring thousands of submitted public comments about research indicating that legal marijuana access is associated with lowered addiction and overdose rates.
In addition to including the three notable marijuana mentions in its new report, the Senate Appropriations Committee has recently adopted a number of cannabis-related amendments on bipartisan votes.
In July, the panel approved measures to protect state medical marijuana laws from federal interference, allow military veterans to receive medical cannabis recommendations from the U.S. Department of Veterans Affairs, remove uncertainty about industrial hemp and protect cannabis growers’ water rights.
A NIDA spokeswoman was unable to immediately confirm when the agency plans to submit the requested report on Schedule I’s research roadblocks.
ACTION OPPORTUNITY: It takes just a minute to urge the Trump administration opioid commission to consider marijuana’s role in addressing and preventing addiction and overdose.
GOP Congressman: Legal Marijuana Has “Possibility To Create Jobs”
Legalizing marijuana might be a way to help lift rural areas of Virginia out of poverty, a Republican who represents part of the state in Congress says.
“The lands out in Southwest are conducive to be able to grow that for medicinal purposes, or whatever it is, for other research purposes, and even recreational use for some areas, if Virginia chooses to legalize it in that way,” Congressman Scott Taylor said on Wednesday. “And if Virginia goes that way I think there is the possibility to create jobs down in the Southwest.”
Taylor, who was answering a caller’s question during an appearance on C-SPAN’s Washington Journal, added that he supports letting states set their own cannabis laws without federal interference.
“I think we should decriminalize it and leave it up to the states,” he said. “I do believe it’s a state decision, not a federal decision.”
Taylor, a freshman member of Congress, is a cosponsor of a pending House bill to remove marijuana from the Controlled Substances Act.
“When I was in the state House we voted to legalize industrial hemp, which is also another product that would grow well in Southwest just as tobacco did,” Taylor added. “So I think there’s product there.”
Advocates believe that Virginia has a good chance of decriminalizing cannabis in 2018. Incoming Gov. Ralph Northam, A Democrat, spoke often about cannabis on the campaign trail, consistently describing criminalization’s impact in stark racial justice terms.
Republican Senate Majority Leader Tommy Norment has announced he will file a decriminalization bill when the new legislative session begins in January.
Vermont Will Legalize Marijuana Within Weeks, Officials Indicate
Vermont appears poised to become the next state to legalize marijuana. And, according to top elected officials, it is likely to do so within a matter of weeks.
Last week, House Speaker Mitzi Johnson, a Democrat, said she expects “it likely will pass in early January.” Days earlier, Gov. Phil Scott, a Republican, said he is “comfortable” signing a cannabis legalization bill into law in early 2018. And on Thursday, Senate President Pro Tempore Tim Ashe, a member of the Progressive Party, said he and his colleagues “look forward to working with the governor to make sure that that bill gets to the finish line.”
(Marijuana Moment’s editor provides some content to Forbes via a temporary exclusive publishing license arrangement.)
Photo courtesy of M a n u e l.
Here’s What Jeff Sessions Discussed In Secret With Anti-Marijuana Activists
Last week, U.S. Attorney General Jeff Sessions held a behind-closed-doors meeting about marijuana with anti-legalization activists.
Now, thanks to the fact that Sessions inadvertently showed an agenda for the meeting to a TV camera that was in the room to capture introductions — along with some high-tech sleuthing — we know what the prohibitionists discussed in secret after reporters were kicked out.
A Twitter user with the handle @MentalMocean was able to enhance a screen capture of the document that Marijuana Moment posted.
The document appears to read:
Bertha Madras: Marijuana is not a substitute for opiates as a pain medication.
Dr. Hoover Adger: The harm from today’s marijuana.
Dr. Bob DuPont: The effect of marijuana on drugged driving.
David Evans: The role that the Food and Drug Administration can and should [obscured]
[obscured] The organizations you can speak for and what you and they are [obscured] people from recreational marijuana use.
[obscured] law enforcement thinks of the commercialization of [obscured] law enforcement would support an enforcement initiative.
[obscured] course of marijuana commercialization in the states if the [obscured] not intervene.
The enhanced photo makes clear that the anti-legalization activists made a concerted pitch during meeting to convince Sessions to launch a federal crackdown on states that have ended cannabis prohibition.
Can any tech wizards enhance this screen grab of an agenda that Jeff Sessions was holding before the start of a drug policy meeting today? pic.twitter.com/7FLvjj1AZd
— Tom Angell 🌳📰 (@tomangell) December 8, 2017
— Sam Gold (@MentalMocean) December 13, 2017
In attendance, according to video of the opening introductions captured by a pool photographer and posted by C-SPAN, were:
- Edwin Meese III, U.S. attorney general under the Reagan administration
- Kevin Sabet, president and CEO of Smart Approaches to Marijuana
- Bertha Madras, a former Office of National Drug Control Policy staffer and a member of President Trump’s Commission on Combating Drug Addiction and the Opioid Crisis
- Robert DuPont, former director of the National Institute on Drug Abuse
- David Evans, executive director of the Drug Free Schools Coalition
- Dr. Hoover Adger, Johns Hopkins Hospital
“I think it’s a big issue for America, for the country, and I’m of the general view that this is not a healthy substance,” Sessions said at the beginning of the gathering. “I think that’s pretty clear. And then have the policy response that we and the federal government needs to be prepared to take and do so appropriately and with good sense.”
“I appreciate the opportunity to hear your analysis on marijuana and some of the related issues,” Sessions told the group. “I do believe, and I’m afraid, that the public is not properly educated on some of the issues related to marijuana. And that would be a matter that we could, all of us together, maybe be helpful in working on and that would allow better policy to actually be enacted.”
The group’s roundtable discussion itself, which took place after initial introductions, was closed to the press.
The gathering comes as the Justice Department’s overall position on marijuana policy remains uncertain. Sessions has in recent weeks sent mixed signals about his plans for federal marijuana enforcement under the Trump administration.
Last month, he testified before Congress that an Obama-era Justice Department memo that generally allows states to implement their own marijuana laws without interference remains in effect. But he separately told reporters at a briefing that his department is actively conducting talks about potential changes to the policy.
Photo courtesy of Gage Skidmore.
Politics2 months ago
This Obscure 45-Year-Old Federal Law Exempts State-Legal Marijuana
Politics2 weeks ago
Trump Administration Considering Marijuana Policy Changes, Sessions Says
Politics2 months ago
Former Surgeon General: Legalize Marijuana; Decrim Not Good Enough
Politics2 months ago
These States Will Probably Vote On Marijuana In 2018
Politics2 months ago
FDA To Review Medical Claims About Marijuana
Politics2 months ago
Marijuana Is A Big Issue In Next Month’s Elections
Politics4 weeks ago
New Sessions Memo: Does It Impact Marijuana?
Science & Health2 months ago
Psychologists Group Slams Barriers To Marijuana Research